MA35601B1 - Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1 - Google Patents

Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1

Info

Publication number
MA35601B1
MA35601B1 MA36620A MA36620A MA35601B1 MA 35601 B1 MA35601 B1 MA 35601B1 MA 36620 A MA36620 A MA 36620A MA 36620 A MA36620 A MA 36620A MA 35601 B1 MA35601 B1 MA 35601B1
Authority
MA
Morocco
Prior art keywords
hydroxymethyl substituted
compounds
pyrrolotriazines
alk1 inhibitors
alk1
Prior art date
Application number
MA36620A
Other languages
English (en)
Inventor
Jurgen Klar
Verena Voehringer
Joachim Telser
Mario Lobell
Frank Submeier
Volkhart Min-Jian Li
Michael Bottger
Stefan Golz
Dieter Lang
Karl-Heinz Schlemmer
Thomas Schlange
Andreas Schall
Wenlang Fu
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47436537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35601(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA35601B1 publication Critical patent/MA35601B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Cette invention porte sur de nouvelles pyrrolo[2,1-f][1,2,4]triazin-4-amines 5-substituées par (hydroxyméthyl)aryle représentées par la formule (i), sur des procédés pour la préparation de tels composés, sur des compositions pharmaceutiques contenant de tels composés et sur l'utilisation de tels composés ou de telles compositions pour le traitement de troubles liés à l'angiogenèse, en particulier de troubles oculaires liés à l'angiogenèse.
MA36620A 2012-03-27 2013-12-27 Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1 MA35601B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12161547 2012-03-27
PCT/EP2012/062366 WO2013004551A1 (fr) 2011-07-01 2012-06-26 Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1

Publications (1)

Publication Number Publication Date
MA35601B1 true MA35601B1 (fr) 2014-11-01

Family

ID=47436537

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36620A MA35601B1 (fr) 2012-03-27 2013-12-27 Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1

Country Status (25)

Country Link
US (1) US9040691B2 (fr)
EP (1) EP2726482B1 (fr)
JP (1) JP5955953B2 (fr)
KR (1) KR20140036269A (fr)
CN (1) CN103764657B (fr)
AP (1) AP3529A (fr)
AR (1) AR087017A1 (fr)
AU (1) AU2012280508A1 (fr)
BR (1) BR112014000049A2 (fr)
CA (1) CA2840518A1 (fr)
CO (1) CO6870031A2 (fr)
CU (1) CU20130170A7 (fr)
DO (1) DOP2013000300A (fr)
EA (1) EA023775B1 (fr)
EC (1) ECSP13013120A (fr)
ES (1) ES2598027T3 (fr)
GT (1) GT201300313A (fr)
IL (1) IL229533A0 (fr)
MA (1) MA35601B1 (fr)
MX (1) MX2013014315A (fr)
PE (1) PE20140570A1 (fr)
PH (1) PH12013502695A1 (fr)
SG (1) SG195100A1 (fr)
UY (1) UY34167A (fr)
WO (1) WO2013004551A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
NO3175985T3 (fr) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
ES2813415T3 (es) 2011-08-10 2021-03-23 Lankenau Inst Medical Res Métodos y composiciones para el tratamiento de enfermedades autoinmunes e inflamatorias
CN104080789B (zh) * 2012-01-31 2016-05-11 南京奥昭生物科技有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
AU2015243261B2 (en) * 2014-04-10 2020-06-25 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders
MX382659B (es) 2014-05-28 2025-03-11 Bayer Cropscience Ag Proceso para la preparación de derivados de tiazol.
ES2807785T3 (es) 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
EP3209665B1 (fr) 2014-10-22 2019-08-14 Bristol-Myers Squibb Company Composés pyrrolotriaziniques aminés substitués en tant qu'inhibiteurs de pi3k
CN107428747A (zh) 2014-11-25 2017-12-01 拜耳制药股份公司 取代的吡啶并苯并二氮杂*酮衍生物及其用途
US10179777B2 (en) 2015-04-16 2019-01-15 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives
WO2017035366A1 (fr) 2015-08-26 2017-03-02 Incyte Corporation Dérivés de type pyrrolo-pyrimidine utilisés comme inhibiteurs des tam
KR102483020B1 (ko) 2016-03-28 2023-01-04 인사이트 코포레이션 Tam 저해제로서의 피롤로트리아진 화합물
CN109111447A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
MA50655B1 (fr) 2017-09-27 2021-11-30 Incyte Corp Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
BR112021020441A2 (pt) 2019-04-12 2021-12-14 Blueprint Medicines Corp Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra
WO2021178779A1 (fr) 2020-03-06 2021-09-10 Incyte Corporation Polythérapie comprenant des inhibiteurs d'axl/mer et de pd-1/pd-l1
WO2024097980A1 (fr) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Inhibiteurs de protéines ret-ldd

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4649046B2 (ja) * 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
RU2356906C2 (ru) 2002-08-08 2009-05-27 Киссеи Фармасьютикал Ко., Лтд. Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP5116687B2 (ja) * 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
WO2007064931A2 (fr) 2005-12-02 2007-06-07 Bayer Healthcare Llc Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
ES2545907T3 (es) 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
EP1873157A1 (fr) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines et sels de ceux-ci, compositions pharmaceutiques contenant ces composes, procedes de preparation associes, et leur utilisation
JP2010508315A (ja) * 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
ATE522249T1 (de) * 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
AR068877A1 (es) * 2007-10-17 2009-12-09 Novartis Ag Derivados heterociclicos de imidazol
KR101324804B1 (ko) * 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds

Also Published As

Publication number Publication date
BR112014000049A2 (pt) 2017-02-07
US20140256718A1 (en) 2014-09-11
AP3529A (en) 2016-01-11
JP2014525902A (ja) 2014-10-02
IL229533A0 (en) 2014-01-30
GT201300313A (es) 2014-11-13
MX2013014315A (es) 2014-01-31
EP2726482B1 (fr) 2016-07-20
PH12013502695A1 (en) 2019-06-14
NZ619453A (en) 2016-01-29
AR087017A1 (es) 2014-02-05
KR20140036269A (ko) 2014-03-25
JP5955953B2 (ja) 2016-07-20
DOP2013000300A (es) 2014-02-28
SG195100A1 (en) 2013-12-30
EP2726482A1 (fr) 2014-05-07
EA201490103A1 (ru) 2014-06-30
UY34167A (es) 2013-01-31
CN103764657B (zh) 2016-05-25
CU20130170A7 (es) 2014-04-24
CU24146B1 (fr) 2016-02-29
AU2012280508A1 (en) 2013-12-12
CO6870031A2 (es) 2014-02-20
AP2014007378A0 (en) 2014-01-31
ECSP13013120A (es) 2014-02-28
PE20140570A1 (es) 2014-04-28
CN103764657A (zh) 2014-04-30
US9040691B2 (en) 2015-05-26
ES2598027T3 (es) 2017-01-24
CA2840518A1 (fr) 2013-01-10
EA023775B1 (ru) 2016-07-29
WO2013004551A1 (fr) 2013-01-10

Similar Documents

Publication Publication Date Title
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA32965B1 (fr) Derives de sulfonamides
MA45020B1 (fr) Dérivés sulfonamides aromatiques
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA34331B1 (fr) Composés pyrazole comme inhibiteurs du récepteur sigma
MA46038B1 (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA38146B1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA34067B1 (fr) Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA41185B1 (fr) Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc
MA34308B1 (fr) Triazolopyridines substituées
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA49127B1 (fr) Dérivés d'indole n-substitués
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA52375B2 (fr) Inhibiteurs de cdk8/19